Endosense

Endosense is a medical technology company based in Geneva, founded in 2003. The company specializes in enhancing the efficacy, safety, and accessibility of catheter ablation procedures for treating cardiac arrhythmias, particularly atrial fibrillation. Endosense is known for pioneering contact force measurement technology with its flagship product, the TactiCath®, which is the first force-sensing ablation catheter in the industry. The TactiCath® catheter provides real-time, objective measurements of the contact force between the catheter tip and the heart wall during ablation procedures. This technology helps optimize the force applied, improving both the safety and effectiveness of treatments. Endosense's solutions address critical needs in cardiac electrophysiology, enabling more controlled and successful catheter ablation, a minimally invasive procedure used when medication fails to treat arrhythmias. The company primarily serves electrophysiologists and healthcare providers specializing in cardiac rhythm disorders. With the growing demand for catheter ablation due to an aging population and increasing prevalence of heart rhythm disorders, Endosense continues to play a significant role in advancing cardiac care.

• Employees 200
• Founded 2003
• Total Funding $76300000